5 Best Debt Free Stocks To Buy
Incyte Corporation (NASDAQ:INCY) is a biopharmaceutical company that engages in the discovery, development, and commercialization of therapeutics for hematology and oncology.
Incyte Corp (INCY)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Baker Bros. Advisors Julian Baker And Felix Baker | 36,178,566 | $2,090,035,758 | +1% | 12.04% |
| 2. | 2,531,618 | $146,251,572 | 0.45% | ||
| 3. | Millennium Management Israel Englander | 2,011,616 | $116,211,056 | +46% | 0.05% |
| 4. | Two Sigma Advisors John Overdeck And David Siegel | 1,686,300 | $97,417,551 | -20% | 0.24% |
| 5. | D E Shaw D. E. Shaw | 1,676,370 | $96,843,895 | -8% | 0.1% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $73.31 | 175,795 | Large Shareholder, Director | 33,419,055 | 2022-03-10 | Filing | |
| $73.31 | 14,490 | Large Shareholder, Director | 2,941,147 | 2022-03-10 | Filing | |
| $71.95 | 1,017 | Large Shareholder, Director | 33,243,260 | 2022-03-10 | Filing | |
| $71.95 | 84 | Large Shareholder, Director | 2,926,657 | 2022-03-10 | Filing | |
| $71.90 | 25,107 | Large Shareholder, Director | 33,242,243 | 2022-03-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $65.13 | 8,449 | Officer | 77,530 | 2023-09-01 | Filing | |
| $63.28 | 21,511 | Officer | 97,583 | 2023-08-01 | Filing | |
| $84.06 | 802 | Officer | 68,524 | 2023-01-31 | Filing | |
| $84.73 | 4,842 | Officer | 68,524 | 2023-01-30 | Filing | |
| $85.07 | 5,644 | Officer | 68,524 | 2023-01-30 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 24,245,969 | $1,400,689,632 | 0.04% | |
| 2. | 22,159,419 | $1,280,149,636 | 0.03% | |
| 3. | 16,416,111 | $948,358,732 | 0.63% | |
| 4. | 9,511,030 | $549,452,203 | 0.03% | |
| 5. | 4,565 | $263,720,000 | 0.09% |
News See All
Jim Simons Stock Portfolio: 12 Biggest Healthcare Stocks
In this piece, we will take a look at the 12 biggest healthcare stocks in Jim Simons' stock portfolio.
Top 20 Drug Companies in the US by Revenue
Following the Covid-19 pandemic, which drastically altered the way of living, the top pharmaceutical or drug companies in the world became the center of attention for people everywhere due to the spike...
Incyte Corporation (NASDAQ:INCY) Q3 2023 Earnings Call Transcript
Operator: Hello, and welcome to the Incyte Third Quarter Earnings Conference Call. [Operator Instructions] A question-and-answer session will follow the formal presentation.
5 Cheap Biotech Stocks Smart Investors Are Piling Into
In this piece, we will take a look at five cheap biotechnology stocks that smart investors are piling into.
Top 30 Oncology Companies in the World
In this article, we shall cover the top 30 oncology companies in the world.
13 Best Beaten Down Stocks To Buy Now
In this article, we will be taking a look at the 13 best beaten down stocks to buy now.
15 Worst Performing Biotech Stocks in 2023
In this article, we discuss 15 worst performing biotech stocks in 2023.
Incyte Corporation (NASDAQ:INCY) Q2 2023 Earnings Call Transcript
Operator: Hello and welcome to the Incyte Second Quarter Earnings Conference Call and Webcast. [Operator Instructions] As a reminder, this conference is being recorded.
Incyte Corporation (NASDAQ:INCY) Q1 2023 Earnings Call Transcript
Operator: Hello and welcome to the Incyte First Quarter 2023 Earnings Call and Webcast. A question-and-answer session will follow the formal presentation.
Billionaire Hedge Funds
